10.1111/j.1476-5381.2011.01235.x 112 NorgaardC
For example, emerging research on GLP-1 receptor agonistssuch as liraglutide and semaglutidehas already demonstrated promising cognitive improvements, enhanced memory, and protection against neurodegenerative changes
As the demand for innovative, effective treatments for diabetes and obesity continues to rise, the GLP-1 market is expected to expand further, with new drug approvals and improved treatment options likely to drive continued success
In comparison, adults who took placebo lost on average about 6 lb, or about 2.4% of their starting body weight
These treatments also work alongside testosterone replacement therapy (TRT) and medical weight loss program, including GLP-1s, helping support energy, metabolism, and sustainable weight management as part of a comprehensive approach to wellness